Loading…
Loading…
HUNTINGDON VALLEY, Pa., July 1, 2026 /PRNewswire/ -- The Board of Trustees of Siren ETF Trust (the "Trust") has determined to close and liquidate the Siren DIVCON Leaders Dividend ETF (CBOE: LEAD) and Siren NexGen Economy ETF (NASDAQ: BLCN), each of which is a series of the Trust (each, a "Fund").
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Integer (ITGR) To Contact Him Directly To Discuss Their Options
/PRNewswire/ -- SRN Advisors, LLC (SRN) announced today that the Siren DIVCON Dividend Defender ETF (CBOE: DFND), an index-based exchange-traded fund ("ETF")
LEAD is comprised of dividend-paying U.S. stocks with a high likelihood of increasing their dividend payments, as determined by a proprietary system. However, LEAD holds mostly low-yielding stocks, making it a unique offering that's best compared with broad-based funds like SPY. Its expected yield is only 0.77%. Using SPY as a comparator, LEAD's total returns were about 34% less since its January 2016 launch. With low-single-digit dividend growth rates, I don't see the appeal.
NARI: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Inari Medical, Inc. May 20, 2024 10:00 AM EDT | Source: Kessler Topaz Meltzer & Check, LLP Radnor, Pennsylvania--(Newsfile Corp. - May 20, 2024) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Inari Medical, Inc. ("Inari Medical") (NASDAQ: NARI) on behalf of investors who purchased or acquired Inari Medical common stock between February 24, 2022 through February 28, 2024, inclusive (the "Class Period"). The action charges Inari Medical with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Inari Medical's materially misleading statements and omissions to the public, Inari Medical's investors have suffered significant losses.The lead plaintiff deadline is July 12, 2024. If you suffered Inari Medical losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/inari-medical-inc?utm_source=PR&utm_medium=link&utm_campaign=nari&mktm=rYou can also contact attorney Jonathan Naji, Esq. of Kessler Topaz by calling (484) 270-1453 or by email at info@ktmc.com. DEFENDANTS' ALLEGED MISCONDUCTOn February 28, 2024, Inari Medical revealed in its Form 10-K for fiscal year 2023 that the company had received a civil investigative demand from the U.S. Department of Justice, Civil Division, in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act, requesting information and documents primarily relating to meals and consulting service payments provided to health care professionals.Following this news, Inari Medical's stock price plummeted over $12 per share, or 21% the very next trading day, from a closing price of $58.26 per share on February 28, 2024, to $46.12 per share on February 29, 2024 - wiping out approximately $700 million in market capitalization in one trading day.WHAT CAN I DO?Inari Medical investors may, no later than July 12, 2024, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP encourages Inari Medical investors who have suffered significant losses to contact the firm directly to acquire more information. The class action complaint against Inari Medical, Michiana Area Electrical Workers' Pension Fund v. Inari Medical, Inc., et al., Case No. 24-cv-03686, is filed in the United States District Court for the Southern District of New York and is pending before the Honorable Jennifer Hutchison Rearden.CLICK HERE TO SIGN UP FOR THE CASE or go to: https://www.ktmc.com/new-cases/inari-medical-inc?utm_source=PR&utm_medium=link&utm_campaign=nari&mktm=rWHO CAN BE A LEAD PLAINTIFF?A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.ABOUT KESSLER TOPAZ MELTZER & CHECK, LLPKessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.CONTACT:Kessler Topaz Meltzer & Check, LLPJonathan Naji, Esq.(484) 270-1453280 King of Prussia RoadRadnor, PA 19087info@ktmc.comMay be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/209807 SOURCE: Kessler Topaz Meltzer & Check, LLP
AKRO Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges Akero Therapeutics, Inc. Investors with Losses to Contact the Firm May 20, 2024 10:45 AM EDT | Source: Kessler Topaz Meltzer & Check, LLP Radnor, Pennsylvania--(Newsfile Corp. - May 20, 2024) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc. ("Akero") (NASDAQ: AKRO). The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Akero's materially misleading statements and omissions to the public, Akero's investors have suffered significant losses.If you suffered Akero losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/akero-therapeutics-inc?utm_source=PR&utm_medium=link&utm_campaign=akro&mktm=rYou can also contact attorney Jonathan Naji, Esq. of Kessler Topaz by calling (484) 270-1453 or by email at info@ktmc.com. The lead plaintiff deadline is June 25, 2024. DEFENDANTS' ALLEGED MISCONDUCTAkero is a clinical stage drug development company which has yet to generate any revenues because the FDA has not approved any of its drug candidates for sale. To finance the company's operations, Akero conducted two secondary stock offerings and one at-the-market stock offering during the Class Period, raising over $577 million. In order to successfully complete these offerings and raise part of the funding, Akero needed to develop and commercialize EFX, Akero's lead product candidate, which was being developed to treat Nonalcoholic steatohepatitis ("NASH") - a serious form of nonalcoholic fatty liver disease that is estimated to affect 17 million Americans.The Class Period begins on September 13, 2022. On that date, Akero filed with the SEC a Form 8-K which reported the 24-week results for Akero's Phase 2b HARMONY study of EFX in patients with pre-cirrhotic NASH. The Form 8-K and the attached press release stated that both the 50 milligram and 28 milligram doses of EFX had achieved statistical significance on primary and secondary histology endpoints after 24 weeks.Two days later, on September 15, 2022, Akero filed with the SEC a prospectus supplement for a secondary offering of Akero common stock, pursuant to, the company eventually sold over 8.8 million shares of Akero common stock at $26 per share, raising gross proceeds of approximately $230 million.Throughout the Class Period, Defendants repeatedly misled investors as to the true nature of the patient population that was being tested in Akero's SYMMETRY study. Specifically, despite telling investors that the study's patient population was limited to those with NASH induced cirrhosis (a fact that was key for data integrity and the likelihood of study success), for approximately 20% of those being tested Akero had not confirmed that the patients had NASH and that NASH had in fact caused their cirrhosis.Akero shocked the market on October 10, 2023 when the company posted disappointing interim data from its Phase 2b SYMMETRY trial for EFX. Specifically, Akero stated that 22% (28mg) and 24% (50mg) of those on EFX and 14% on placebo indicated at least one stage improvement in fibrosis with no worsening of NASH at week 36, the trial's primary endpoint, but that these changes were not statistically significant. In addition, Akero added that 12 patients, including 11 in EFX groups, discontinued the trial due to drug-related adverse events. On this news, Akero's stock price fell $30.39 per share, or 62.61%, to close at $18.15 per share on October 10, 2023.WHAT CAN I DO?Akero investors may, no later than June 25, 2024, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP encourages Akero investors who have suffered significant losses to contact the firm directly to acquire more information. The class action complaint against Akero, Klobus v. Akero Therapeutics, Inc., et al., Case No. 24-cv-02534, is filed in the United States District Court for the Northern District of California.CLICK HERE TO SIGN UP FOR THE CASE or go to: https://www.ktmc.com/new-cases/akero-therapeutics-inc?utm_source=PR&utm_medium=link&utm_campaign=akro&mktm=rWHO CAN BE A LEAD PLAINTIFF?A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.ABOUT KESSLER TOPAZ MELTZER & CHECK, LLPKessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.CONTACT:Kessler Topaz Meltzer & Check, LLPJonathan Naji, Esq.(484) 270-1453280 King of Prussia RoadRadnor, PA 19087info@ktmc.comMay be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/209804 SOURCE: Kessler Topaz Meltzer & Check, LLP
ADSK Shareholder Reminder: Autodesk, Inc. Shareholders of Deadline in Securities Fraud Class Action Lawsuit May 20, 2024 11:30 AM EDT | Source: Kessler Topaz Meltzer & Check, LLP Radnor, Pennsylvania--(Newsfile Corp. - May 20, 2024) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Autodesk, Inc. ("Autodesk") (NASDAQ: ADSK). The action charges Autodesk with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Autodesk's materially misleading statements and omissions to the public, Autodesk's investors have suffered significant losses.If you suffered Autodesk losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/autodesk-inc?utm_source=PR&utm_medium=link&utm_campaign=adsk&mktm=rYou can also contact attorney Jonathan Naji, Esq. of Kessler Topaz by calling (484) 270-1453 or by email at info@ktmc.com. The lead plaintiff deadline is June 24, 2024. DEFENDANTS' ALLEGED MISCONDUCTThe Class Period begins on June 1, 2023, when Autodesk filed with the SEC its quarterly report on Form 10-Q for the period ended April 30, 2023. Therein, and throughout the Class Period, Defendants assured investors as to the accuracy of financial reporting, the disclosure of any material changes to the company's internal control over financial reporting and the disclosure of all fraud.Then, on April 1, 2024, Autodesk disclosed that the company would be unable to timely file its annual report due to "an internal investigation with the assistance of outside counsel and advisors, regarding the Company's free cash flow and non-GAAP operating margin practices." On this news, Autodesk's stock price fell $10.73, or 4.1%, to close at $248.71 per share on April 2, 2024.On April 16, 2024, Autodesk issued a press release providing an update on the internal investigation, stating that the company "will not file its Annual Report…within the 15-day extension period…due to the ongoing investigation" and "expects to receive a notice from the Nasdaq Stock Market…that it is not in compliance with the timely filing requirement for continued listing under Nasdaq" listing rules. On this news, Autodesk's stock price fell $13.32 per share, or 5.84%, to close at $214.92 per share on April 17, 2024. WHAT CAN I DO?Autodesk investors may, no later than June 24, 2024, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP encourages Autodesk investors who have suffered significant losses to contact the firm directly to acquire more information. The class action complaint against Autodesk, Barkasi v. Autodesk, Inc., et al., Case No. 24-cv-02431, is filed in the United States District Court for the Northern District of California.CLICK HERE TO SIGN UP FOR THE CASE or go to: https://www.ktmc.com/new-cases/autodesk-inc?utm_source=PR&utm_medium=link&utm_campaign=adsk&mktm=rWHO CAN BE A LEAD PLAINTIFF?A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.ABOUT KESSLER TOPAZ MELTZER & CHECK, LLPKessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.CONTACT:Kessler Topaz Meltzer & Check, LLP(484) 270-1453280 King of Prussia RoadRadnor, PA 19087info@ktmc.comMay be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/209796 SOURCE: Kessler Topaz Meltzer & Check, LLP
GoodRx Holdings, Inc. (GDRX) Investors: June 21, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP May 19, 2024 12:15 PM EDT | Source: Kessler Topaz Meltzer & Check, LLP Radnor, Pennsylvania--(Newsfile Corp. - May 19, 2024) - The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against GoodRx Holdings, Inc. (NASDAQ: GDRX) ("GoodRx" or the "Company") on behalf of investors who purchased or acquired GoodRx common stock between September 23, 2020, and November 8, 2022, inclusive (the "Class Period"). This action, captioned Barsuli v. GoodRx Holdings, Inc., et al., Case No. Case 2:24-cv-03282- DDP-AJR was filed in the United States District Court for the Central District of California.Important Deadline Reminder: Investors who purchased or otherwise acquired GoodRx common stock during the Class Period may, no later than June 21, 2024, move the Court to serve as lead plaintiff for the class. If you suffered GoodRx losses, you may CLICK HERE or GO TO: https://www.ktmc.com/new-cases/goodrx-holdings-inc-1?utm_source=PR&utm_medium=link&utm_campaign=gdrx&mktm=rYou can also contact attorney Jonathan Naji, Esq. of Kessler Topaz by calling (484) 270-1453 or by email at info@ktmc.com. DEFENDANTS' MISCONDUCTGoodRx operates a price comparison platform for prescription drugs which, in many cases, offers consumers access to lower prices (through discount codes and coupons) for their medications. GoodRx generates most of its revenue from contracts with pharmacy benefit managers ("PBMs") who agree to pay GoodRx a commission on prescription drug purchases made by consumers who use GoodRx's discount codes and coupons at participating pharmacies. GoodRx also generates a portion of its revenue from subscription plans like the "Kroger Rx Savings Club," which provides "access [to] lower prescription prices at" pharmacies operated by The Kroger Co. ("Kroger").In connection with GoodRx's initial public offering on September 23, 2020, and throughout the remainder of the Class Period, Defendants continuously touted the Company's strong relationships with pharmacies as a significant element of its business plan. Among other things, GoodRx repeatedly highlighted the Kroger Rx Savings Club. Critically, however, Defendants never informed investors of the material risk that Kroger, which accounted for nearly 25% of GoodRx's prescription transactions revenue, could unilaterally refuse to accept GoodRx's discounts. On May 9, 2022, investors began to learn the truth about the risks of GoodRx's over-dependence on Kroger (including the risk that, notwithstanding the Kroger Rx Savings Club, Kroger could unilaterally refuse to accept GoodRx's discounts), when GoodRx revealed that, late in the first quarter of 2022, "a grocery chain had taken actions that impacted acceptance of discounts from most PBMs for a subset of drugs" and that this "impacted the acceptance of many PBM discounts for certain drugs at this grocer's stores." GoodRx further acknowledged that this disruption "could have an estimated revenue impact of roughly $30 million" in the second quarter of 2022-resulting in the Company announcing disappointing second quarter 2022 revenue guidance of only about $190 million. While Defendants refused to identify the grocer by name, analysts and media outlets quickly recognized that the unnamed grocery chain was Kroger.On this news, the price of GoodRx common stock plummeted $2.78 per share, or more than 25%, from a close of $10.75 per share on May 9, 2022, to close at $7.97 per share on May 10, 2022. On November 8, 2022, Defendants provided further information on the severity of the revenue impact from the Kroger disruption-with the Company estimating that the "impact of the grocer issue on third quarter [prescription transactions revenue] was approximately $40 million" and that the Company expected "a combined $45 million to $50 million estimated impact to prescription transactions revenue" for the fourth quarter of 2022. Defendants further acknowledged that the Company was seeking to enter into contractual relationships with pharmacies to prevent similar disruptions from occurring in the future. On this news, the price of GoodRx common stock declined an additional $1.18 per share, or more than 22%, from a close of $5.24 per share on November 8, 2022, to close at $4.06 per share on November 9, 2022.WHAT CAN I DO?GoodRx investors may, no later than June 21, 2024, move the Court to serve as lead plaintiff for the class, through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP encourages GoodRx investors who have suffered significant losses to contact the firm directly to acquire more information.CLICK HERE to sign up for the case or GO TO: https://www.ktmc.com/new-cases/goodrx-holdings-inc-1?utm_source=PR&utm_medium=link&utm_campaign=gdrx&mktm=rWHO CAN BE A LEAD PLAINTIFF?A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.ABOUT KESSLER TOPAZ MELTZER & CHECK, LLPKessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries.For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com. CONTACT:Kessler Topaz Meltzer & Check, LLPJonathan Naji, Esq.280 King of Prussia RoadRadnor, PA 19087(844) 887-9500 (toll free)info@ktmc.comMay be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/209777 SOURCE: Kessler Topaz Meltzer & Check, LLP
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for LEAD and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.